Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

Gemcitabine 13Albumin-Bound Paclitaxel 8Taxes 6130-nm albumin-bound paclitaxel 6Fluorouracil 5Oxaliplatin 4dehydroftorafur 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Leucovorin 3Irinotecan 3Losartan 2Cisplatin 2tocilizumab 1selicrelumab 1niraparib 1irinotecan sucrosofate 1indusatumab 1folfirinox 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1S 1 (combination) 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Pancreatic Adenocarcinoma × Oxaliplatin × Clear all
NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02562716 2022-10-19

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 16 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03528785 2021-08-02

nITRo

Centro Ricerche Cliniche di Verona

Phase 2 Unknown
67 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡